Staburo took part in the 2016 PSI Conference „Promoting Statistical Insight and Collaboration in Drug Development“ that took place in Berlin between 22 and 25 May.
The conference featured a wide range of interesting topics for statisticians in the pharmaceutical and healthcare industry, including health technology assessment, biomarkers in translational medicine, estimands and central statistical monitoring. Presenters from industry, academia and regulatory agencies shared their valuable knowledge in talks, discussion rounds and poster sessions.
Staburo took part in the second Career Day at the Max-Planck-Institute of Psychiatry on 11 May 2016 in Munich. Josef Höfler and Roland Stieger gave a short overview of Staburo services and insights into the work of biostatisticians and statistical programmers in clinical research. During lunch and coffee breaks, PhD students and researchers directly approached us with their questions. Other companies that participated were HEXAL, Grünenthal, IMS Consulting, Covance and Kelly. It was great to get the opportunity to present our company to such bright people!
We are very pleased to welcome Dr. Gabriele Bleckert in our team. Gabriele Bleckert will support our customers with her experience in the areas of statistical programming and biostatistics. We are looking forward to a great cooperation!
We have completely redesigned the Staburo homepage to better inform you about our services. The simplified navigation enables you to find your desired services faster, and with the modern design, reading the website on your smartphone or tablet has been improved. (more…)
Network meta-analyses (NMAs) are a methods, which allows indirect comparisons of several medications. Indirect comparisons play an important role in the assessment of the cost-benefit ratio of drugs.
(more…)
Biomarker play an important role in modern pharmaceutical development because they allow a treatment adjusted for the patient’s individual circumstances. Recommendation for specific therapies for example based on the patient’s very own gene mutation profile (keyword “Precision Medicine”) take the place of the predominant “one-size-fits-all” approach.
Recent Comments